2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.
Primary completion pushed from Aug 3, 2025 to Sep 2028
Also in this update: Enrollment increased: 42 → 66 participants; Study completion pushed from Dec 2026 to Dec 2028
Peter MacCallum Cancer Centre, AustraliaPhase 1/2 NCT05521412 Registry history of NCT05521412 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jun 2032 to Nov 1, 2032
Peter MacCallum Cancer Centre, AustraliaNot applicable NCT06882499 Registry history of NCT06882499 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-24 | NCT07840001 Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal… | Phase 2 | Not Yet Recruiting |
| Phase 1 | 6 | |
| Phase 1/2 | 5 | |
| Phase 2 | 10 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT05154162 | PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI | Prostate Cancer | Active, Not Recruiting | 2026-03-03 |
| Phase 2 | ||||
| NCT07217938 | Novel Treatment of Radiation Associated Dysphagia With Statins | Radiation-associated Dysphagia | Recruiting | 2026-09-04 |
| NCT06812715 | Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After… | Chronic Lymphocytic Leukemia | Recruiting | 2026-09-03 |
| NCT05560659 | Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative… | Oligometastatic Prostate Cancer | Recruiting | 2025-07-11 |
| NCT06414148 | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy… | Relapsed/Refractory Large B-cell Lymphoma | Recruiting | 2025-06-05 |
| NCT07840001 | Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal… | Locally Advanced Clear Cell Renal Cell Carcinoma | Not Yet Recruiting | 2026-09-24 |
| NCT05878288 | Deep sequencIng in Cutaneous Squamous CEll caRciNomas | Cutaneous Squamous Cell Carcinoma | Active, Not Recruiting | 2026-09-21 |
| NCT07434180 | Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary | Cancer of Unknown Primary | Not Yet Recruiting | 2026-02-25 |
| NCT04343885 | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177… | Metastatic Hormone Naive Prostate Cancer | Active, Not Recruiting | 2025-07-11 |
| NCT04234061 | Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel… | Mantle Cell Lymphoma Recurrent | Active, Not Recruiting | 2024-11-07 |
| NCT05864742 | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in… | Mantle Cell Lymphoma Refractory | Active, Not Recruiting | 2024-08-12 |
| Phase 1/2 | ||||
| NCT05521412 | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate… | Prostate Cancer | Recruiting | 2026-09-21 |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting | 2025-04-06 |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting | 2025-02-07 |
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy | Prostatic Neoplasms | Active, Not Recruiting | 2024-11-08 |
| NCT03980171 | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve… | Follicular Lymphoma | Active, Not Recruiting | 2024-07-29 |
| Phase 1 | ||||
| NCT07541391 | Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen… | Relapsed/Refractory Multiple Myeloma | Recruiting | 2026-05-27 |
| NCT05053854 | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | Neuroendocrine Tumors | Recruiting | 2025-02-20 |
| NCT05666700 | CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in… | Extramedullary Myeloma | Active, Not Recruiting | 2026-07-28 |
| NCT07090369 | Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab… | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Not Yet Recruiting | 2025-07-29 |
| NCT03874884 | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant… | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Active, Not Recruiting | 2025-05-14 |
| NCT03900884 | Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer | Breast Neoplasm Female | Active, Not Recruiting | 2024-11-07 |
| Not applicable | ||||
| NCT07387978 | A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in… | Oral Mucositis | Recruiting | 2026-02-04 |
| NCT07051525 | Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological… | Leukemia | Recruiting | 2025-12-15 |
| NCT05570227 | Metabolic Phenotypes in Melanoma | Melanoma | Recruiting | 2023-07-06 |
Prostate Cancer (10) · Head & Neck Cancer (4) · Non-Hodgkin Lymphoma (4) · Breast Cancer (3) · Leukemia (2) · Mantle Cell Lymphoma (2) · Melanoma (2) · Multiple Myeloma (2) · Chronic Lymphocytic Leukemia (CLL) (1) · DLBCL (1)